Trial Profile
A Randomized, Open-label, Single-dose, Four-sequence, Four -Period Crossover Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Tamsulosin (Primary)
- Indications Benign prostatic hyperplasia
- Focus Pharmacokinetics
- Sponsors GL PharmTech
- 07 Mar 2014 New trial record